سعر نابيزول 40مجم 14 كبسولة 2024

Napizole omeprazole 40 mg capsules, 14 capsules (Global Napi); proton pump inhibitor for peptic ulcer and reflux disease.

• Short-term treatment of active duodenal ulcer and of active benign gastric ulcer in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Eradication of Helicobacter pylori (with amoxicillin and clarithromycin, or clarithromycin) to reduce the risk of duodenal ulcer recurrence in adults.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Treatment of symptomatic GERD and treatment/maintenance of healing of erosive esophagitis due to acid-mediated GERD in patients 2 years and older.Population: Patients 2 years and olderDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions in adults (≥2%): headache, abdominal pain, nausea, diarrhea, vomiting and flatulence.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Known hypersensitivity (including anaphylaxis, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria) to the formulation or to any substituted benzimidazole.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Patients receiving rilpivirine-containing products.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Symptomatic response does not preclude gastric malignancy; consider further evaluation in adults with suboptimal response or early relapse.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute tubulointerstitial nephritis may occur at any time during PPI therapy; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• PPI therapy may be associated with an increased risk of Clostridioides difficile-associated diarrhea.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• ClopidogrelAvoid concomitant use: omeprazole inhibits CYP2C19 and reduces the formation of clopidogrel's active metabolite and its antiplatelet activity.DailyMed (U.S. National Library of Medicine)
• RilpivirineContraindicated: PPIs decrease rilpivirine exposure.DailyMed (U.S. National Library of Medicine)
• St John's wort / rifampinCYP2C19/CYP3A4 inducers can substantially decrease omeprazole concentrations; avoid concomitant use.DailyMed (U.S. National Library of Medicine)

• There are no adequate and well-controlled studies in pregnant women; available epidemiologic data fail to demonstrate an increased risk of major congenital malformations or other adverse pregnancy outcomes with first-trimester omeprazole use.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Limited data suggest omeprazole may be present in human milk; there are no data on effects on the breastfed infant or milk production; weigh benefits of breastfeeding against the mother's clinical need.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Omeprazole: Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase (proton pump) at the secretory surface of the gastric parietal cell (US Zegerid label).